{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Galcanezumab",
    "query": {
      "intervention": "Galcanezumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Galcanezumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T19:59:02.218Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02104765",
      "title": "A Study of LY2951742 in Healthy Japanese and Caucasian Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "LY2951742",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "20 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2014-06",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2019-06-14",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02104765"
    },
    {
      "nct_id": "NCT05492695",
      "title": "Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Diamond Headache Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2022-10-01",
      "completion_date": "2023-09-28",
      "has_results": false,
      "last_update_posted_date": "2023-09-29",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05492695"
    },
    {
      "nct_id": "NCT02614287",
      "title": "A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 270,
      "start_date": "2015-11-30",
      "completion_date": "2018-08-14",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 13,
      "location_summary": "Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02614287"
    },
    {
      "nct_id": "NCT02836613",
      "title": "A Study of Galcanezumab in Healthy Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 160,
      "start_date": "2016-07",
      "completion_date": "2017-11-09",
      "has_results": true,
      "last_update_posted_date": "2019-03-13",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 3,
      "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02836613"
    },
    {
      "nct_id": "NCT04616326",
      "title": "A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Migraine"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 312,
      "start_date": "2020-11-25",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 45,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04616326"
    },
    {
      "nct_id": "NCT04417361",
      "title": "Galcanezumab for Vestibular Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vestibular Migraine"
      ],
      "interventions": [
        {
          "name": "Galcanezumab Prefilled Syringe",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-09-18",
      "completion_date": "2023-09-29",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04417361"
    },
    {
      "nct_id": "NCT02397473",
      "title": "A Study Of Galcanezumab In Participants With Episodic Cluster Headache",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Episodic Cluster Headache"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 109,
      "start_date": "2015-05-22",
      "completion_date": "2018-06-04",
      "has_results": true,
      "last_update_posted_date": "2019-09-09",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Palo Alto, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02397473"
    },
    {
      "nct_id": "NCT04179474",
      "title": "Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Ubrogepant",
          "type": "DRUG"
        },
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-09-26",
      "completion_date": "2019-12-23",
      "has_results": true,
      "last_update_posted_date": "2021-03-10",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 2,
      "location_summary": "Springfield, Missouri • West Bend, Wisconsin",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04179474"
    },
    {
      "nct_id": "NCT04158752",
      "title": "Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Trigeminal Neuralgia",
        "Glossopharyngeal Neuralgia"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2020-07-24",
      "completion_date": "2023-01-04",
      "has_results": true,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04158752"
    },
    {
      "nct_id": "NCT05127486",
      "title": "A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine",
        "Episodic Migraine"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 580,
      "start_date": "2021-12-06",
      "completion_date": "2023-05-23",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-09-04T19:59:02.218Z",
      "location_count": 77,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127486"
    }
  ]
}